This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CRGX CARGO Therapeutics (CRGX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About CARGO Therapeutics Stock (NASDAQ:CRGX) Get CARGO Therapeutics alerts:Sign Up Key Stats Today's Range$4.47▼$4.4750-Day Range$4.46▼$4.6152-Week Range$3.78▼$4.77VolumeN/AAverage Volume1.43 million shsMarket Capitalization$216.17 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California. Read More Receive CRGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CARGO Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRGX Stock News HeadlinesShareholder Alert: The Ademi Firm Continues to Investigate Whether CARGO Therapeutics, Inc. is Obtaining a Fair Price for its Public ShareholdersSeptember 15, 2025 | businesswire.comCARGO Therapeutics Acquired by Concentra BiosciencesAugust 19, 2025 | tipranks.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.July 6 at 1:00 AM | Reagan Gold Group (Ad)Jefferies Raises Price Target for Cargo Therapeutics (CRGX), Keeps Hold RatingJuly 29, 2025 | msn.comCARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CARGO Therapeutics, Inc. - CRGXJuly 25, 2025 | businesswire.comURGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger - CRGX, HSON, BRZH, and ENZBJuly 25, 2025 | prnewswire.comCRGX - Cargo Therapeutics Inc Financials | MorningstarJuly 19, 2025 | morningstar.comMCARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of ...July 11, 2025 | morningstar.comMSee More Headlines CRGX Stock Analysis - Frequently Asked Questions How were CARGO Therapeutics' earnings last quarter? CARGO Therapeutics, Inc. (NASDAQ:CRGX) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.26. When did CARGO Therapeutics IPO? CARGO Therapeutics (CRGX) raised $300 million in an initial public offering (IPO) on Friday, November 10th 2023. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share. What other stocks do shareholders of CARGO Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CARGO Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings11/12/2024Today7/06/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRGX Previous SymbolNASDAQ:CRGX CIK1966494 Webcargo-tx.com Phone650-379-6143FaxN/AEmployees116Year Founded2019Price Target and Rating Average Price Target for CARGO Therapeutics$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+11.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($4.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$167.50 million Net MarginsN/A Pretax MarginN/A Return on Equity-43.21% Return on Assets-37.26% Debt Debt-to-Equity RatioN/A Current Ratio12.37 Quick Ratio12.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.91 per share Price / Book0.91Miscellaneous Outstanding Shares48,360,000Free Float46,952,000Market Cap$216.17 million OptionableN/A Beta0.30 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CRGX) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersThree companies about to leapfrog Nvidia [And transform the entire industry]The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | Sponsored$2 an acre. They paid $412.Government land listed at $2 an acre sold for $412 - 206 times asking price. Demand got so intense the feds do...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CARGO Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CARGO Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.